Alliance Pharma buys rights to Novartis' obstetric drug Syntometrine
(Reuters) - Specialty pharmaceutical company Alliance Pharma Plc said it bought all existing rights to obstetric drug Syntometrine from Novartis AG for $11.5 million. Full story
Novartis says study shows Gilenya benefits patients with MS
ZURICH (Reuters) - Novartis said studies show its Gilenya drug helped keep patients with multiple sclerosis free of the disease. Full story
U.S. sues Novartis over kickbacks, second case this week
NEW YORK (Reuters) - The U.S. government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs. Full story
UK health cost body backs Novartis asthma drug in fresh U-turn
LONDON (Reuters) - Britain's health cost-effectiveness watchdog NICE said it planned to recommend the use of Novartis's severe asthma drug Xolair after prevaricating for months over whether it should be paid for on the taxpayer-funded National Health Service (NHS). Full story
EU approves Novartis drug for gout
ZURICH (Reuters) - The European Commission has approved Novartis' drug Ilaris for patients with an often painful form of inflammatory arthritis, the drugmaker said on Friday. Full story
Novartis golden handshake angers shareholders, politicians
ZURICH (Reuters) - Pharma group Novartis' <NOVN.VX> decision to pay up to 72 million Swiss francs ($77.94 million) to outgoing chairman Daniel Vasella has unleashed a wave of indignation among activist shareholders and politicians. Full story
Sponsored Links
Articles
Related Photos
A Novartis logo is pictured on its headquarters building in Mumbai
A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. REUTERS/Vivek Prakash
File picture of a logo on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln near Basel
File picture of a logo on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln near Basel February 22, 2013. India's highest court has dismissed, April 1, 2013, Swiss drugmaker Novartis AG's petition seeking patent protection for its cancer drug Glivec, a serious blo
File picture showing a general view of Swiss drugmaker Novartis headquarters in Basel
File picture showing a general view of Swiss drugmaker Novartis headquarters in Basel September 1, 2011. India's highest court has dismissed, April 1, 2013, Swiss drugmaker Novartis AG's petition seeking patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms whi
A logo is pictured on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln
A logo is pictured on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln near Basel February 22, 2013. REUTERS/Arnd Wiegmann
Lehner, member of the Board of Directors of Swiss drug maker Novartis addresses the the annual shareholders general meeting in Basel
Ulrich Lehner, member of the Board of Directors of Swiss drug maker Novartis addresses the the annual shareholders general meeting in Basel February 22, 2013. Novartis scrapped plans on February 19, 2013 to pay its outgoing chairman Daniel Vasella 72 million Swiss francs ($78 million) to stop him wo
